title: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia.
abstract: The objective of this study was to examine the efficacy of bupropion for smoking cessation in patients with schizophrenia. Adults with schizophrenia who smoked more than 10 cigarettes per day and wished to try to quit smoking were recruited from community mental health centers, enrolled in a 12-week group cognitive behavioral therapy intervention, and randomly assigned to receive either bupropion sustained-release 300 mg/d or identical placebo. Fifty-three adults, 25 on bupropion and 28 on placebo, were randomized, completed at least 1 postbaseline assessment and were included in the analysis. The primary outcome measures were 7-day point prevalence abstinence in the week after the quit date (week 4) and at the end of the intervention (week 12). Subjects in the bupropion group were significantly more likely to be abstinent for the week after the quit date (36% [9/25] vs. 7% [2/28], P = 0.016) and at end of the intervention (16% [4/25] vs. 0%, P = 0.043). Subjects in the bupropion group also had a higher rate of 4-week continuous abstinence (weeks 8-12) (16% [4/25] vs. 0%, P = 0.043) and a longer duration of abstinence (4.2 [3.2] weeks vs. 1.8 [0.96] weeks, t = 2.30, P = 0.037). The effect of bupropion did not persist after discontinuation of treatment. Subjects in the bupropion group had no worsening of clinical symptoms and had a trend toward improvement in depressive and negative symptoms. We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation.
authors.affiliation: Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA. a_eden_evins@hms.harvard.edu
authors.forename: A Eden
authors.initials: AE
authors.lastname: Evins
authors.forename: Corinne
authors.initials: C
authors.lastname: Cather
authors.forename: Thilo
authors.initials: T
authors.lastname: Deckersbach
authors.forename: Oliver
authors.initials: O
authors.lastname: Freudenreich
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Culhane
authors.forename: Casey M
authors.initials: CM
authors.lastname: Olm-Shipman
authors.forename: David C
authors.initials: DC
authors.lastname: Henderson
authors.forename: David A
authors.initials: DA
authors.lastname: Schoenfeld
authors.forename: Donald C
authors.initials: DC
authors.lastname: Goff
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Rigotti
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016642:Bupropion / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D012907:Smoking / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D016540:Smoking Cessation / Q000379:methods*
chemical_list: D003692:Delayed-Action Preparations; D016642:Bupropion